(-0.02%) 5 477.25 points
(-0.07%) 38 791 points
(0.03%) 19 927 points
(0.25%) $80.53
(1.29%) $2.82
(0.15%) $2 332.40
(-0.34%) $29.29
(-0.22%) $968.80
(0.01%) $0.932
(-0.15%) $10.64
(0.07%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers...
Stats | |
---|---|
Šios dienos apimtis | 0 |
Vidutinė apimtis | 1.55M |
Rinkos kapitalizacija | 0.00 |
EPS | $-1.100 ( Q2 | 2022-08-05 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.24 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.443 (2.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-10-14 | Lesser Brian Andrew | Sell | 42 593 | Common Stock |
2022-10-14 | Lesser Brian Andrew | Sell | 37 500 | Stock Option (Right to Buy) |
2022-10-14 | Potts Jeannette | Sell | 37 500 | Stock Option (Right to Buy) |
2022-10-14 | Potts Jeannette | Sell | 43 958 | Common Stock |
2022-10-14 | Fanucci Marsha | Sell | 7 250 | Common Stock |
INSIDER POWER |
---|
-96.79 |
Last 97 transactions |
Buy: 1 770 820 | Sell: 4 300 300 |
Tūris Koreliacija
Forma Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Forma Therapeutics Koreliacija - Valiuta/Žaliavos
Forma Therapeutics Finansinės ataskaitos
Annual | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-4.21 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-4.21 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-3.22 |
FY | 2019 |
Pajamos: | $100.56M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-3.15 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Forma Therapeutics
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.